Regardless of the effect being direct or indirect, irisin is still interesting pharmaceutically, since it could potentially inhibit the loss of β-cell mass in gluco- and lipotoxic conditions, which is common in T2D. The gene discussed is FNDC5; the disease is type 2 diabetes mellitus.